|
1
|
Hanski C, Hofmeier M, Schmitt-Gräff A, et
al: Overexpression or ectopic expression of MUC2 is the common
property of mucinous carcinomas of the colon, pancreas, breast, and
ovary. J Pathol. 182:385–391. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Velcich A, Yang W, Heyer J, et al:
Colorectal cancer in mice genetically deficient in the mucin Muc2.
Science. 295:1726–1729. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Piancatelli D, Romano P, Sebastiani P,
Adorno D and Casciani CU: Local expression of cytokines in human
colorectal carcinoma: evidence of specific interleukin-6 gene
expression. J Immunother. 22:25–32. 1999. View Article : Google Scholar
|
|
5
|
Lieubeau B, Heymann MF, Henry F, Barbieux
I, Meflah K and Grégoire M: Immunomodulatory effects of
tumor-associated fibroblasts in colorectal-tumor development. Int J
Cancer. 81:629–636. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Giri D, Ozen M and Ittmann M:
Interleukin-6 is an autocrine growth factor in human prostate
cancer. Am J Pathol. 159:2159–2165. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adler HL, McCurdy MA, Kattan MW, Timme TL,
Scardino PT and Thompson TC: Elevated levels of circulating
interleukin-6 and transforming growth factor-beta 1 in patients
with metastatic prostatic carcinoma. J Urol. 161:182–187. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Esfandi F, Mohammadzadeh Ghobadloo S and
Basati G: Interleukin-6 level in patients with colorectal cancer.
Cancer Lett. 244:76–78. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Galizia G, Orditura M, Romano C, et al:
Prognostic significance of circulating IL-10 and IL-6 serum levels
in colon cancer patients undergoing surgery. Clin Immunol.
102:169–178. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ueda T, Shimada E and Urakawa T: Serum
levels of cytokines in patients with colorectal cancer: possible
involvement of interleukin-6 and interleukin-8 in hematogenous
metastasis. J Gastroenterol. 29:423–429. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kinoshita T, Ito H and Miki C: Serum
interleukin-6 level reflects the tumor proliferative activity in
patients with colorectal carcinoma. Cancer. 85:2526–2531. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chung YC and Chang YF: Serum interleukin-6
levels reflect the disease status of colorectal cancer. J Surg
Oncol. 83:222–226. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li YY, Hsieh LL, Tang RP, Liao SK and Yeh
KY: Macrophage-derived interleukin-6 up-regulates MUC1, but
down-regulates MUC2 expression in the human colon cancer HT-29 cell
line. Cell Immunol. 256:19–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Atsumi T, Singh R, Sabharwal L, et al:
Inflammation amplifier, a new paradigm in cancer biology. Cancer
Res. 74:8–14. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lu TJ, Lai WY, Huang CY, et al: Inhibition
of cell migration by autophosphorylated mammalian sterile 20-like
kinase 3 (MST3) involves paxillin and protein-tyrosine
phosphatase-PEST. J Biol Chem. 281:38405–38417. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shan YS, Fang JH, Lai MD, et al:
Establishment of an orthotopic transplantable gastric cancer animal
model for studying the immunological effects of new cancer
therapeutic modules. Mol Carcinog. 50:739–750. 2011. View Article : Google Scholar
|
|
17
|
Ancrile B, Lim KH and Counter CM:
Oncogenic Ras-induced secretion of IL6 is required for
tumorigenesis. Genes Dev. 21:1714–1719. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fridlender ZG, Sun J, Kim S, et al:
Polarization of tumor-associated neutrophil phenotype by TGF-beta:
‘N1’ versus ‘N2’ TAN. Cancer Cell. 16:183–194. 2009.PubMed/NCBI
|
|
19
|
Ajioka Y, Allison LJ and Jass JR:
Significance of MUC1 and MUC2 mucin expression in colorectal
cancer. J Clin Pathol. 49:560–564. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yonezawa S, Sueyoshi K, Nomoto M, et al:
MUC2 gene expression is found in noninvasive tumors but not in
invasive tumors of the pancreas and liver: its close relationship
with prognosis of the patients. Hum Pathol. 28:344–352. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li A, Goto M, Horinouchi M, et al:
Expression of MUC1 and MUC2 mucins and relationship with cell
proliferative activity in human colorectal neoplasia. Pathol Int.
51:853–860. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bresalier RS, Niv Y, Byrd JC, et al: Mucin
production by human colonic carcinoma cells correlates with their
metastatic potential in animal models of colon cancer metastasis. J
Clin Invest. 87:1037–1045. 1991. View Article : Google Scholar
|
|
23
|
Blank M, Klussmann E, Krüger-Krasagakes S,
et al: Expression of MUC2-mucin in colorectal adenomas and
carcinomas of different histological types. Int J Cancer.
59:301–306. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ohlsson L, Israelsson A, Oberg A, et al:
Lymph node CEA and MUC2 mRNA as useful predictors of outcome in
colorectal cancer. Int J Cancer. 130:1833–1843. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kang H, Min BS, Lee KY, et al: Loss of
E-cadherin and MUC2 expressions correlated with poor survival in
patients with stages II and III colorectal carcinoma. Ann Surg
Oncol. 18:711–719. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Elzagheid A, Emaetig F, Buhmeida A, et al:
Loss of MUC2 expression predicts disease recurrence and poor
outcome in colorectal carcinoma. Tumour Biol. 34:621–628. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Van der Sluis M, De Koning BA, De Bruijn
AC, et al: Muc2-deficient mice spontaneously develop colitis,
indicating that MUC2 is critical for colonic protection.
Gastroenterology. 131:117–129. 2006.PubMed/NCBI
|
|
28
|
Eichbaum C, Meyer AS, Wang N, et al:
Breast cancer cell-derived cytokines, macrophages and cell
adhesion: implications for metastasis. Anticancer Res.
31:3219–3227. 2011.PubMed/NCBI
|
|
29
|
Luboshits G, Shina S, Kaplan O, et al:
Elevated expression of the CC chemokine regulated on activation,
normal T cell expressed and secreted (RANTES) in advanced breast
carcinoma. Cancer Res. 59:4681–4687. 1999.PubMed/NCBI
|
|
30
|
Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki
Y and Abe A: Correlation of tissue and plasma RANTES levels with
disease course in patients with breast or cervical cancer. Clin
Cancer Res. 7:285–289. 2001.PubMed/NCBI
|
|
31
|
Zhang GJ and Adachi I: Serum interleukin-6
levels correlate to tumor progression and prognosis in metastatic
breast carcinoma. Anticancer Res. 19:1427–1432. 1999.
|
|
32
|
Salgado R, Junius S, Benoy I, et al:
Circulating interleukin-6 predicts survival in patients with
metastatic breast cancer. Int J Cancer. 103:642–646. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kishimoto T: The biology of interleukin-6.
Blood. 74:1–10. 1989.
|
|
34
|
Jones SA, Scheller J and Rose-John S:
Therapeutic strategies for the clinical blockade of IL-6/gp130
signaling. J Clin Invest. 121:3375–3383. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yen MC, Lin CC, Chen YL, et al: A novel
cancer therapy by skin delivery of indoleamine 2,3-dioxygenase
siRNA. Clin Cancer Res. 15:641–649. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin CC, Chou CW, Shiau AL, et al:
Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally
overexpressing endogenous neu. Mol Ther. 10:290–301. 2004.
View Article : Google Scholar : PubMed/NCBI
|
